Ulcerative colitis-related postoperative enteritis treated with anti-tumor necrosis factor therapy: two case reports and a literature review

Shimoda, Fumiko; Kuroha, Masatake; Chiba, Hirofumi; Abe, Ikuo; Yano, Kota; Inomata, Yushi; Takahashi, Takahiro; Moroi, Rintaro; Shiga, Hisashi; Kakuta, Yoichi; Fujishima, Fumiyoshi; Masamune, Atsushi

doi:10.1007/s12328-021-01485-5

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intraoperative explorations revealed sporadic superficial ulcers and obliteration of the vascular pattern of the mucosal layer. These findings concurred with the clinical features of UC-related severe enteritis (UCRSE) reported by Kohyama et al [ 13 ] and Shimoda et al [ 14 ]. No deaths were recorded in patients with DPOI.…”

Section: Resultssupporting

confidence: 92%

Preoperative Biologics Exposure Predisposes Ulcerative Colitis Patients to a Distinct Delayed Postoperative Ileus Syndrome After Colectomy

et al. 2022

View full text Add to dashboard Cite

Background:Postoperative ileus (POI) remains the most common complication after colectomy for inflammatory bowel disease (IBD). Delayed POI (DPOI) can develop late (>14 days) after colectomy in clinical settings, with unknown etiology. The aim of this study was to address a novel entity of POI after colectomy for ulcerative colitis (UC). Material/Methods:The data of 263 UC patients who underwent colectomy from Jan 1, 2013 to May 31, 2021 were collected. DPOI was defined as POI occurring on or after postoperative day (POD) 14 with apparent resolution from obligatory POI. Univariate and multivariate analysis were conducted to identify the risk factors for DPOI. Results:The rate of canonical prolonged POI and DPOI were 11.7% (31/263) and 9.9% (26/263), respectively. The pathophysiological process of DPOI demonstrated an ileus-dysbiosis-recovery triad. Two DPOI cases were diagnosed with UC-related severe enteritis and underwent re-laparotomy. Multivariate analysis showed preoperative biologics exposure was an independent risk factor for DPOI (OR 3.100 95% CI 1.261-7.619, P=0.018) and the number of biologics session/course moderately predicted the occurrence of DPOI (AUC=0.639, 95% CI=0.578-0.697, P=0.0129). Conclusions:A distinct pattern of ileus was identified in a tertiary IBD center. Clarification of this syndrome complemented the spectrum of post-IPAA complications and offered experience to treat this condition.

show abstract

Section: Resultssupporting

confidence: 92%

Preoperative Biologics Exposure Predisposes Ulcerative Colitis Patients to a Distinct Delayed Postoperative Ileus Syndrome After Colectomy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In a patient with mild bleeding from UC-related enteritis, 5-aminosalicylic acid and corticosteroids did not confer complete recovery, who eventually responded well to IFX treatment with no progressive worsening (12). In another case, IFX was ineffective for colitis but improved postoperative enteritis and led to endoscopic healing (11). Considering this evidence, IFX was administered to the patient after corticosteroids.…”

Section: B C Amentioning

confidence: 99%

“…treatment option for acute severe UC in several guidelines, as this treatment induces remission and reduces mortality (7-10). For UCRSE, corticosteroids were also most frequently used as a first-line therapy to relieve symptoms rapidly (11). Corporaal et al reviewed 42 cases with UC-related enteritis, virtually all of whom were either cured or controlled, especially with high intravenous doses of corticosteroids (5).…”

Section: B C Amentioning

confidence: 99%

Case report: Successful treatment of ulcerative colitis-related post-colectomy enteritis refractory to multiple therapies with ustekinumab

Guo,

He,

Wang

2024

Front. Immunol.

View full text Add to dashboard Cite

Ulcerative colitis-related severe post-colectomy enteritis is a rare condition. A few cases have undergone successful treatment with corticosteroids, Cyclosporine, Azathioprine, and Infliximab. We aim to evaluate the treatment outcome of ustekinumab in this rare case. Here we describe a 56-year-old woman with post-colectomy enteritis refractory to multiple therapies. Finally, the patient was administered with ustekinumab treatment. Under monitoring, the feces volume of the patient decreased from 5000-7000 mL per day to 1700-2000 mL. Over a one-year follow-up period, the patient gradually gained body weight, with the stoma drainage of formed brown stool. And the villi of the small intestinal mucosa restore growth. To our knowledge, this is the first report that indicates ustekinumab could be a treatment selection for ulcerative colitis-related severe post-colectomy enteritis.

show abstract

A case of ulcerative colitis-related postoperative enteritis treated with granulocyte and monocyte apheresis

Adachi

Sugiyama

Yamaguchi

et al. 2022

Clin J Gastroenterol

View full text Add to dashboard Cite

Ulcerative colitis-related postoperative enteritis treated with anti-tumor necrosis factor therapy: two case reports and a literature review

Cited by 5 publications

References 23 publications

Preoperative Biologics Exposure Predisposes Ulcerative Colitis Patients to a Distinct Delayed Postoperative Ileus Syndrome After Colectomy

Preoperative Biologics Exposure Predisposes Ulcerative Colitis Patients to a Distinct Delayed Postoperative Ileus Syndrome After Colectomy

Case report: Successful treatment of ulcerative colitis-related post-colectomy enteritis refractory to multiple therapies with ustekinumab

A case of ulcerative colitis-related postoperative enteritis treated with granulocyte and monocyte apheresis

Contact Info

Product

Resources

About